Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion
Summary
NIH registered a Phase 3 clinical trial (NCT07537933) to evaluate whether immediate intra-arterial tirofiban after complete recanalization improves recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. The trial will enroll approximately 520 participants and compare tirofiban treatment with no tirofiban, measuring good functional outcome at 90 days and symptomatic intracranial hemorrhage risk. Primary completion is expected April 17, 2026.
What changed
NIH ClinicalTrials.gov registered a new Phase 3 clinical trial (NCT07537933) titled 'Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion.' The trial will study tirofiban, a glycoprotein IIb/IIIa inhibitor, administered intra-arterially immediately after mechanical thrombectomy achieves complete recanalization in acute ischemic stroke patients. Approximately 520 adult participants will be randomly assigned to receive tirofiban or no tirofiban, with 90-day functional outcomes and bleeding event safety endpoints.
Pharmaceutical companies supplying tirofiban for investigational use, clinical investigators conducting the stroke trial, and institutional review boards overseeing human subjects research should note the trial registration. The study focuses on anterior circulation large-vessel occlusion, which represents a significant subset of acute ischemic stroke cases amenable to endovascular treatment. Sites should ensure investigational drug accountability, protocol compliance, and adverse event reporting align with IND requirements.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion
Phase 3 NCT07537933 Kind: PHASE3 Apr 17, 2026
Abstract
The goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. The main questions it aims to answer are:
Does immediate intra-arterial tirofiban after complete recanalization increase the number of participants with good functional outcome at 90 days? Does this treatment increase the risk of symptomatic intracranial hemorrhage or other important bleeding events?
Researchers will compare immediate intra-arterial tirofiban with no intra-arterial tirofiban after complete recanalization to see if tirofiban improves recovery and is safe.
Participants will:
Be enrolled after mechanical thrombectomy achieves complete recanalization Be randomly assigned to receive intra-arterial tirofiban or no intra-arterial tirofiban Receive follow-up assessments during hospitalization and at 90 days
Conditions: Acute Ischemic Stroke, Large-vessel Occlusion, Endovascular Treatment
Interventions: Tirofiban
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.